Background Fibromyalgia is a clinically defined chronic condition of unknown etiology
characterized by chronic widespread pain that often co‐exists with sleep disturbances …

Duloxetine (DLX), milnacipran (MLN), and pregabalin (PGB) are the only drugs licensed by
the US Food and Drug Administration (FDA) for fibromyalgia syndrome (FMS). Evidence on …

Objective To determine whether low dosages (4.5 mg/day) of naltrexone reduce
fibromyalgia severity as compared with the nonspecific effects of placebo. In this replication …

Duloxetine is a serotonin-norepinephrine reuptake inhibitor approved for the treatment of
patients affected by major depressive disorder (MDD), generalized anxiety disorder (GAD) …

Background: Duloxetine is a selective dual neuronal serotonin (5‐Hydroxytryptamine, 5‐HT)
and norepinephrine reuptake inhibitor (SSNRI). It is indicated in the United States for …

Fibromyalgia syndrome is a chronic pain disorder and defies definitively efficacious therapy.
In this review, we summarize the results from the early treatment research as well as recent …

Fibromyalgia (FM), a complex chronic pain disorder affecting a heterogeneous patient
population, is an area of active basic and clinical research. Although diagnostic criteria for …

Chronic pain exerts a tremendous burden on individuals and societies. If one views chronic
pain as a single disease entity, then it is the most common and costly medical condition. At …

Fibromyalgia (FM) is a manifestation of chronic widespread pain (CWP) and tenderness with
a prevalence of 2% in the general population. 1 Clinically, patients who have FM present …

Objective. To determine response with duloxetine versus placebo in patients with
osteoarthritis (OA) of the knee using the Outcome Measures in Rheumatoid Arthritis Clinical …